Datapoint: FDA Approves TG Therapeutics’ Ukoniq

The FDA on Feb. 5 granted accelerated approval to TG Therapeutics’ Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma that has not responded to previous treatments. Ukoniq’s trial data suggests it may be safer than its rival PI3K inhibitors, including Gilead Sciences’ Zydelig and Bayer’s Aliqopa, and the FDA will not require a black box warning on the new drug. For the treatment of marginal zone lymphoma, Zydelig currently holds preferred formulary placement for 17% of covered lives, compared to Aliqopa’s 4%.

SOURCE: MMIT Analytics, as of 2/10/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today